Description: Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.
Home Page: acticor-biotech.com
Bâtiment Inserm U1148
Paris,
75877
France
Phone:
33 9 70 46 86 40
Officers
| Name | Title |
|---|---|
| Dr. Gilles Avenard M.D. | Founder, CEO & Director |
| Mr. Philippe Billiald Ph.D., Pharm.D. | Scientific Founder |
| Ms. Martine Jandrot-Perrus M.D., Ph.D. | Scientific Founder |
| Mr. Eric Cohen | Chief Financial Officer |
| Ms. Sophie Lebel-Binay Ph.D. | Chief Scientific Officer & GM |
| Mr. Aymeric Humblot | Head of Fin. & Admin. |
| Dr. Yannick Pletan M.D. | GM & Chief Medical Officer |
| Ms. Laurie Jullien | Head of Regulatory Affairs |
| Ms. Kristell Lebozec | Head of Pharmaceutical Devel. |
| Ms. Victoria Rutman Pharm.D. | Head of Quality Assurance |
Exchange: PA
Country: FR : France
Currency: Euro (€)
| GIC Sector: | Communication Services |
|---|---|
| GIC Group: | Media & Entertainment |
| GIC Industry: | Media |
| GIC Sub-Industry: | Advertising |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 18.2352 |
| Price-to-Sales TTM: | 5.7132 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |